Small Cell Lung Cancer – Current Treatment – Detailed Expanded Analysis: Treatment Sequencing (US)
KEY BENEFITS AND USES
Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
Drill down into physicians’ treatment sequences and understand who to position against and how to defend share.
Identify untapped treatment scenarios and key competitors to aid trial design.
Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
Discover untapped populations to expand product share and drive strategic decisions.
QUESTIONS ANSWERED
Where is my product positioned versus competitors’ products in the treatment journey?
What are physicians’ most frequent treatment sequences? Who is benefiting, and how can I defend my asset’s share and position?
What are the market-relevant treatment scenarios according to oncology experts?
Where are the untapped business opportunities on which I can capitalize?
How can I optimize trial design and ensure a competitive edge for my pipeline asset?
GEOGRAPHIES
United States
PRIMARY MARKET RESEARCH
Survey of 100 U.S. medical oncologists
PRODUCT DESCRIPTION
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary-market-research-based insights from physicians.
Small Cell Lung Cancer - Current Treatment - Detailed Expanded Analysis: Treatment Sequencing (US)
Treatment Sequencing Small-Cell Lung Cancer US September 2021
Pragati Tripathi
Sudha Malhotra, M.S., Ph.D., is an analyst on the Oncology team at Clarivate. She is responsible for performing secondary market analysis, including patent research, pricing, and clinical trial assessment in the major pharmaceutical markets covering a wide range of oncology indications. She obtained her doctorate degree in life sciences from the National Institute of Immunology in New Delhi, India, and has authored several peer-reviewed journal articles. She holds a bachelor’s degree in microbiology and a master’s degree in biomedical sciences, both from the University of Delhi.